Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
3 Growth Stocks for In-the-Know Investors
07:35am, Wednesday, 16'th Dec 2020
They aren't household names, but they're experiencing significant catalysts for growth.
The InvestorPlace Q&A: Genomics, Telehealth and the Future of Healthcare with the ANEW ETF
03:13pm, Monday, 14'th Dec 2020
One aspect of the ANEW ETF is focused on the bleeding edge of medical advances. Here's what you need to know if you're considering investing.
Why Editas Medicine Stock Is Skyrocketing for the Fourth Day in a Row
11:40am, Thursday, 10'th Dec 2020
The biotech just filed to advance its second pipeline candidate into clinical testing.
Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDA
04:01pm, Wednesday, 09'th Dec 2020
EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease
Why Editas Medicine Stock Is Rising for a Third Consecutive Day
11:27am, Wednesday, 09'th Dec 2020
Momentum continues from the biotech's weekend presentation of promising data for its experimental sickle cell disease therapy.
Why Editas Medicine Stock Jumped Again Today
03:41pm, Tuesday, 08'th Dec 2020
Momentum continued from the biotech's positive update announced over the weekend.
How You Can Profit From the Best-Managed Drugmaker on Earth
06:30am, Tuesday, 08'th Dec 2020
One metric shows that decades of dominance treating diabetes has created unrivaled profitability.
Why Editas Medicine Stock Is Soaring Today
11:41am, Monday, 07'th Dec 2020
Investors liked the biotech's update about experimental gene-editing therapy EDIT-301.
Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathies
Editas Medicine: Plagued By Uncertainty, Awed By The Potential
04:03am, Tuesday, 01'st Dec 2020
Editas has foundational expertise in CRISPR technology. It has recently entered clinical trials using its platform in a rare eye disease.
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
04:01pm, Tuesday, 10'th Nov 2020
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company's newly appoin
Editas Medicine Appoints Lisa A. Michaels, M.D.
09:00am, Monday, 09'th Nov 2020
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Lisa A. Michaels, M.D., as the Company's Execu
Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q3 2020 Results - Earnings Call Transcript
10:26pm, Thursday, 05'th Nov 2020
Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q3 2020 Results - Earnings Call Transcript
Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update
04:01pm, Thursday, 29'th Oct 2020
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursda
Crispr Therapeutics’ Gene-Edited Treatment Stopped Cancer in Some Patients
02:02pm, Wednesday, 21'st Oct 2020
Using a gene-editing technique that won a recent Nobel Prize, Crispr Therapeutics cleared blood cancers in patients with off-the-shelf immune cells. Previously, a patient’s own cells were required.
